Stock Watch: The Competition Has It
An Existing Standard Of Care Provides A High Barrier To Late-Comers
Executive Summary
Apart from assuming that its new drug will always be a blockbuster, the other common mistake made by biotech companies and investors is that there will invariably be a viable market for its drug. The competition will have other ideas.